Related Experiment Video

Updated: Jan 27, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.0K

Heart failure with preserved ejection fraction

Otto A Smiseth, Sverre E Kjeldsen, Øyvind Senstad Andersen

    Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
    |March 29, 2019
    PubMed

    Insights

    Heart failure with normal ejection fraction, often caused by hypertension and stiff cardiac muscle, is diagnosed by clinical signs and echocardiography. Treatment involves managing underlying conditions and using similar drugs as for reduced ejection fraction heart failure.

    Area of Science:

    • Cardiology
    • Internal Medicine
    • Clinical Research

    Background:

    • Heart failure with normal ejection fraction affects approximately 50% of heart failure patients.
    • Cardiac muscle stiffness is a key factor, often stemming from hypertension-induced ventricular hypertrophy.

    Purpose of the Study:

    • To review the diagnostic criteria and management of heart failure with normal ejection fraction.
    • To highlight the role of diastolic dysfunction and objective diagnostic markers.

    Main Methods:

    • Conducted literature searches in PubMed.
    • Included 15 relevant articles and nine from a personal literature archive.

    Main Results:

    • Diagnosis requires clinical heart failure symptoms and objective signs of diastolic dysfunction.
    • Increased left ventricular filling pressure (via echocardiography) is a primary objective sign.
    • Ventricular hypertrophy and elevated natriuretic peptides support the diagnosis.

    Conclusions:

    • Treatment focuses on underlying conditions and symptoms.
    • Pharmacological approaches generally align with those used for heart failure with reduced ejection fraction.
    Abstract

    More Related Videos

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

    Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

    Published on: February 13, 2021

    7.0K
    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

    A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

    Published on: February 18, 2022

    2.3K

    Related Concept Videos

    Pathophysiology of Heart Failure01:17

    Pathophysiology of Heart Failure

    Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
    3.3K
    Heart Failure I: Introduction01:27

    Heart Failure I: Introduction

    Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
    793
    Heart Failure II: Pathophysiology01:29

    Heart Failure II: Pathophysiology

    Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
    854
    Heart Failure Drugs: Diuretics01:22

    Heart Failure Drugs: Diuretics

    Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
    906
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    258
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    302